PAA 10.3% 37.5¢ pharmaust limited

Oral Treatment for Covid 19, Human Phase I Trials

  1. 11,411 Posts.
    lightbulb Created with Sketch. 5727
    An Australian Listed Company Pharmaust ASXAA has released today.
    They are eagerly awaiting commencing Phase I Human Trial for a Covid 19 Oral Treatment..


    PAA;ASX released further data today that confirmed Monepantel and Monepantal Sulfone
    demonstrated significant benefits against SARs 1 and SARs 2 based Virus.

    July 26 (Reuters) - Pharmaust Ltd (PAA) :
    MONEPANTEL AND MONEPANTEL SULFONE SIGNIFICANTLY PROTECT AGAINST COVID-19 VIRUS
    MEDIATED CELL DEATHMPL AND MPLS APPEAR TO INHIBIT VIRAL INFECTION BY TARGETING
    LATE-STAGE EVENTS IN COVID-19 VIRUS LIFE-CYCLEEVALUATION OF MPL IN COVID-19
    PATIENTS BEING ASSESSED IN EUROPE FOR WHEN GMP GRADE TABLETS ARE MADE


    The Company has Tablet production underway and is communicating with CRO's Corporate Research Organisations
    seeking a Registered Clinical site capable of Trialing Monepantel MPL is a Regulated clinical environment In Vivo ( Human Trial Candidates )


    The benefits of an Oral Treatment for Covid 19 allows for greater robust delivery where temperature controlled fluid vaccines are difficult to transport.
    Also Oral Tablet form would not have to be administered by clinicians and allows for airdrop into remote locations.

    The Update from Pharmaust reiterates the previous positive results from Trialing at the prestigious WEHI Institute where Marc Pelligrinin an Australian leading virologist commented "the results from testing MPL against Covid are simply remarkable"

    The Viral Load reduction was a staggering 50% in the first 24 hours growing to 95% reduction in Viral Load with in 72 hours.

    Infection Viral load Reduction from 31,762 mpl reduced to 469 mpl.... in a 72 hour period.

    https://hotcopper.com.au/data/attachments/3399/3399539-800dc2bce5f7d409c469b21270523f92.jpg

    so far the data indicates MPL has the ability to be delivered during and prior to viral load (Infection occurring)

    The Company is awaiting further news of Tablet delivery to progress further In Vivo Trialing .
    https://hotcopper.com.au/data/attachments/3399/3399570-dd88eab22bea236d1b39867ad87c89e4.jpg
    Exciting times ahead for this company as Trialing on K9's with Lymphoma Cancers has delivered positive results that
    have paved the way for Human Trialing
    https://hotcopper.com.au/data/attachments/3399/3399607-b000f5cdab5d5056fd0eec81bbfe111a.jpg


    Monepantel the companies lead drug candidate will also commence trialing against MND with the ANZCTR
    application already filed.....
    https://hotcopper.com.au/data/attachments/3399/3399615-cb3466ff8fc2bd6c181b5a50ce51f23b.jpg


    The company is also awaiting results from the Olivia Newton John Foundation for Cancer with MPL being trialed
    in depth against multiple Human cancers,,, hoping to replicate the previous ONJF results where MPL demonstrated
    cancer fighting ability in 26 of 30 Human Cancers..
    https://hotcopper.com.au/data/attachments/3399/3399624-8b11d947c69978ebfa8cc5bc7c720002.jpg

    Last edited by NZ Trader: 26/07/21
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
37.5¢
Change
0.035(10.3%)
Mkt cap ! $146.4M
Open High Low Value Volume
34.5¢ 38.0¢ 34.5¢ $542.7K 1.474M

Buyers (Bids)

No. Vol. Price($)
1 14511 37.0¢
 

Sellers (Offers)

Price($) Vol. No.
37.5¢ 18443 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
37.0¢
  Change
0.035 ( 8.82 %)
Open High Low Volume
34.5¢ 38.0¢ 34.5¢ 757697
Last updated 15.59pm 28/03/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.